who have had limited options and continue to face poor outcomes. FRUZAQLA is the first novel chemotherapy-free treatment option approved for patients in the U.S. regardless of biomarker status in more than a decade,” said Teresa Bitetti, president of the ...
Source: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications Among the approved combination immunotherapies, ICI plus antiangiogenic agents warrants special attention as several combinations have become first-line therapy for major types ...
Gmax is a clinical stage biopharmaceutical company established in 2010 and headquartered inHangzhou, China. It's a global company focusing on R&D, production and commercialization of antibody drugs targeting GPCRs. Gmax main...
A regulatory agency usually requires two independent positive trials of the same new drug for approval. If two different new drugs are approved with the -margin approach by using the same active control, it implies that four noninferiority trials share the same active control. Sharing the same ...
2017Del Brutto OH, Nash TE, White AC Jr., Raj... H O.,Del,Brutto,... - 《Journal of the Neurological Sciences》 被引量: 36发表: 2017年 Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET) In Belgium, new and costly ...
The emergence of nintedanib, tocilizumab, and rituximab has greatly expanded the treatment options for skin sclerosis and SSc-ILD, opening a new era of SSc treatment. This paper provides an overview of these three drugs approved in major countries, focusing on the results of clinical trials that...